Karyopharm Therapeutics
Karyopharm Therapeutics is a pharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines for cancer and other major diseases, with a focus on oral Selective Inhibitor of Nuclear Export (SINE) technology.
Company Overview
Karyopharm Therapeutics is a pharmaceutical company driven by innovation in the discovery, development, and commercialization of medicinal products aimed at improving the lives of patients suffering from cancer and other major diseases. The company's headquarters are located in Newton, Massachusetts, USA, with an additional office in Givatayim, Israel.
SINE Technology Leadership
Karyopharm is an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, which targets a fundamental mechanism of oncogenesis. Their proprietary XPO1 inhibition technology has shown potential in restoring the cell's innate ability to combat certain cancers by increasing the accumulation of tumor suppressor proteins and oncoprotein mRNAs within the nucleus.
Drug Candidates and Pipeline
Karyopharm has four unique drug candidates in clinical development targeting both hematologic and solid tumors. Their lead drug candidate further features next-generation programs in ongoing clinical trials for earlier lines of treatment and various tumor types. Their drug pipeline includes investigational medicines such as XPOVIO, currently being tested in multiple myeloma and diffuse large B-cell lymphoma (DLBCL), and selinexor, studied in combination with other therapies for various cancers.
Clinical Trials and Expanded Access
Karyopharm's clinical trials are conducted globally, including locations in the United States, Europe, and Asia. The company also offers an Expanded Access Program (EAP) for patients with serious, chronic, or life-threatening diseases who have exhausted available treatment options. Investigational medicines are provided through treating physicians who obtain relevant regulatory approval and adhere to applicable safety-reporting regulations.
Support for Medical Education and Research
Karyopharm supports medical education grants in multiple disease states, including Multiple Myeloma, Endometrial Cancer, Myelofibrosis, and Diffuse Large B-Cell Lymphoma. The company is also committed to backing independent research that aligns with its areas of interest, ensuring continued progress in addressing complex diseases through novel therapeutics.